NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma
NUCKS1 overexpression is a novel biomarker for recurrence-free survival in cervical squamous cell carcinoma
复制标题
DOI：
10.1007/s13277-014-2035-5
复制
发表时间：
2014-08-01
期刊：
影响因子：
--
通讯作者：
Lou, Ge
中科院分区：
文献类型：
--
作者：
Gu, Lina;Xia, Bairong;Lou, Ge
核酪蛋白激酶和细胞周期蛋白依赖性激酶底物 1 (NUCKS1) 在各种癌症组织中过度表达，因此可能有助于肿瘤发生。然而，NUCKS1 在宫颈鳞状细胞癌 (CSCC) 中的表达状况仍不清楚。采用免疫组织化学方法检测 30 例宫颈上皮内瘤变 (CIN) 和 125 例 CSCC 中 NUCKS1 蛋白的表达情况，并与 20 例正常宫颈标本进行比较。分析NUCKS1蛋白过表达与CSCC患者临床病理特征和临床结局的相关性。 NUCKS1 在正常组织中表达呈阴性或弱表达，但在 21 个 (70.0%) CIN 和 44 个 (35.2%) CSCC 中表达较高。 NUCKS1过表达与国际妇产科联合会分期晚期（P = 0.016）、组织学分级差（P = 0.040）、肿瘤体积大（P = 0.016）、宫旁受累（P = 0.025）、深部间质浸润（P = 0.043）、淋巴结转移（P = 0.034）和复发（P < 0.001）。多变量分析表明NUCKS1过表达是无复发生存（RFS）的独立因素（风险比，2.193；95％置信区间，1.060至4.535；P = 0.034）。总之，NUCKS1 过表达可能与 CSCC 的肿瘤进展和复发相关，因此可以作为预测这些患者 RFS 的新分子标志物。
Nuclear casein kinase and cyclin-dependent kinase substrate 1 (NUCKS1) is overexpressed in various cancer tissues and may therefore contribute to oncogenesis. However, the status of NUCKS1 expression in cervical squamous cell carcinoma (CSCC) remains unknown. Immunohistochemistry was used to determine the expression of NUCKS1 protein in 30 cervical intraepithelial neoplasias (CINs) and 125 CSCCs compared with 20 normal cervical specimens. The correlationships of NUCKS1 protein overexpression with the clinicopathologic characteristics and clinical outcomes in patients with CSCC were analysed. The status of NUCKS1 expression was negative or weak in normal tissues, but high in 21 (70.0 %) CINs and in 44 (35.2 %) CSCCs. NUCKS1 overexpression was associated with advanced International Federation of Gynaecology and Obstetrics stage (P = 0.016), poor histologic grade (P = 0.040), large tumour size (P = 0.016), parametrial involvement (P = 0.025), deep stromal infiltration (P = 0.043), lymph node metastasis (P = 0.034) and recurrence (P < 0.001). Multivariate analysis suggested that NUCKS1 overexpression was an independent factor for recurrence-free survival (RFS) (hazard ratio, 2.193; 95 % confidence interval, 1.060 to 4.535; P = 0.034). In conclusion, NUCKS1 overexpression may be associated with tumour progression and recurrence in CSCCs and may thus serve as a new molecular marker for the prediction of RFS in these patients.